Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2012
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 02 Mar 2012 Actual end date (Apr 2006) added as reported by ClinicalTrials.gov.
- 02 Mar 2012 Actual patient number is 34 according to ClinicalTrials.gov.
- 24 Mar 2009 New trial record.